Viamet Pharmaceuticals has raised $60m in a series D round featuring Novartis, Eli Lilly and Astellas, days after withdrawing its IPO plans.
US-based biotechnology company Viamet Pharmaceuticals has raised $60m in a series D round which included the corporate venturing units of pharmaceutical companies Novartis, Astellas and Eli Lilly.
The round came after Viamet cancelled its plans to go public in a $75m initial public offering, for which the company filed in July this year.
Novartis Venture Funds, Lilly Ventures and Astellas Venture Management were joined by Brandon Point Industries, Woodford Investment Management, Lurie Holdings, Intersouth Partners and Hatteras Venture Partners…
